These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 19479954)
21. Requirement of the extracellular cysteine at position six for CD40/CD40 dimer formation and CD40-induced IL-8 expression. Girouard J; Reyes-Moreno C; Darveau A; Akoum A; Mourad W Mol Immunol; 2005 May; 42(7):773-80. PubMed ID: 15829265 [TBL] [Abstract][Full Text] [Related]
22. CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system. Chen K; Huang J; Gong W; Zhang L; Yu P; Wang JM Cell Mol Immunol; 2006 Jun; 3(3):163-9. PubMed ID: 16893496 [TBL] [Abstract][Full Text] [Related]
23. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Vardouli L; Lindqvist C; Vlahou K; Loskog AS; Eliopoulos AG Cancer Gene Ther; 2009 Nov; 16(11):848-60. PubMed ID: 19461675 [TBL] [Abstract][Full Text] [Related]
24. CD154 and its receptors in inflammatory vascular pathologies. Hassan GS; Merhi Y; Mourad WM Trends Immunol; 2009 Apr; 30(4):165-72. PubMed ID: 19282242 [TBL] [Abstract][Full Text] [Related]
25. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Engel D; Seijkens T; Poggi M; Sanati M; Thevissen L; Beckers L; Wijnands E; Lievens D; Lutgens E Semin Immunol; 2009 Oct; 21(5):308-12. PubMed ID: 19616449 [TBL] [Abstract][Full Text] [Related]
26. Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative. Margolles-Clark E; Kenyon NS; Ricordi C; Buchwald P Chem Biol Drug Des; 2010 Oct; 76(4):305-13. PubMed ID: 20636329 [TBL] [Abstract][Full Text] [Related]
27. Classification of mutations in the human CD40 ligand, gp39, that are associated with X-linked hyper IgM syndrome. Bajorath J; Seyama K; Nonoyama S; Ochs HD; Aruffo A Protein Sci; 1996 Mar; 5(3):531-4. PubMed ID: 16509032 [TBL] [Abstract][Full Text] [Related]
28. Transfection and ligation of CD40 in human oral keratinocytes affect proliferation, adhesion and migration but not apoptosis in vitro. Villarroel Dorrego M; Whawell SA; Speight PM; Barrett AW Clin Exp Dermatol; 2006 Mar; 31(2):266-71. PubMed ID: 16487107 [TBL] [Abstract][Full Text] [Related]
29. Counteractive functions are encrypted in the residues of CD154. Bandyopadhyay S; Chandel HS; Singh S; Roy S; Krishnasastry MV; Saha B Hum Immunol; 2015 Sep; 76(9):673-80. PubMed ID: 26429321 [TBL] [Abstract][Full Text] [Related]
30. CD40 is required for development of islet inflammation in the RIP-CD154 transgenic mouse model of type 1 diabetes. Haase C; Markholst H Ann N Y Acad Sci; 2007 Jun; 1107():373-9. PubMed ID: 17804565 [TBL] [Abstract][Full Text] [Related]
32. Up-regulation of the expression of costimulatory molecule CD40 in hepatocytes by hepatitis B virus X antigen. Tang Y; Chen Y; Ni B; Yang D; Guo S; Wu Y Biochem Biophys Res Commun; 2009 Jun; 384(1):12-7. PubMed ID: 19336218 [TBL] [Abstract][Full Text] [Related]
33. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Lievens D; Eijgelaar WJ; Biessen EA; Daemen MJ; Lutgens E Thromb Haemost; 2009 Aug; 102(2):206-14. PubMed ID: 19652870 [TBL] [Abstract][Full Text] [Related]
34. [Effect of different patterns activation forms of CD40 on cloning of CD40 mutant and its proliferation and phenotype in RPMI8226 cell line]. Zheng L; Ma HB; Qi CJ; Dong QM; Zhang XG Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):101-4. PubMed ID: 18681310 [TBL] [Abstract][Full Text] [Related]
35. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6. Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472 [TBL] [Abstract][Full Text] [Related]
36. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582 [TBL] [Abstract][Full Text] [Related]
37. CD40 and its ligand in atherosclerosis. Lutgens E; Lievens D; Beckers L; Donners M; Daemen M Trends Cardiovasc Med; 2007 May; 17(4):118-23. PubMed ID: 17482093 [TBL] [Abstract][Full Text] [Related]
38. Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing. Eshel D; Toporik A; Efrati T; Nakav S; Chen A; Douvdevani A Mol Immunol; 2008 Dec; 46(2):250-7. PubMed ID: 18849075 [TBL] [Abstract][Full Text] [Related]
39. The effect of microenvironmental CD40 signals on TRAIL- and drug-induced apoptosis in follicular lymphoma cells. Nuutinen U; Ropponen A; Eeva J; Eray M; Pellinen R; Wahlfors J; Pelkonen J Scand J Immunol; 2009 Dec; 70(6):565-73. PubMed ID: 19906199 [TBL] [Abstract][Full Text] [Related]
40. Small multivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function. Trouche N; Wieckowski S; Sun W; Chaloin O; Hoebeke J; Fournel S; Guichard G J Am Chem Soc; 2007 Nov; 129(44):13480-92. PubMed ID: 17935324 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]